探索“脾主为卫”环节对糖脂代谢稳态的调节机制
Explore Regulation Mechanism of “The Spleen for Defend” on Homeostasis of Glucose and Fat Metabolism
DOI: 10.12677/TCM.2021.103048, PDF,   
作者: 李 莉：广西中医药大学，药学院，广西 南宁；王 涛：天津中医药大学，中医药研究院，天津
关键词: 脾主为卫；益气活血法；金芪降糖方；糖脂代谢病；The Spleen for Defend； Qi-Invigorating and Blood-Activation Therapy； “Jinqi jiangtang” Formula； Glycolipid Metabolic Disease
摘要: 目的：运用益气活血法探索“脾主为卫”环节调节糖脂代谢紊乱的潜在分子机制。方法：采用Western Blot法研究金芪降糖方对KKAy小鼠肝脏和肌肉中PI3K/AKT信号通路的影响；观察金芪降糖方在体外对HepG2细胞TG蓄积的作用和机制。结果表明：金芪降糖方明显上调KKAy小鼠骨骼肌内PI3K、p-PI3K、AKT、p-AKT蛋白的表达；金芪降糖方及其组分均具有降低HepG2细胞TG蓄积的作用，且具有明显的量效关系；应用分别加入抑制剂或激动剂的方法后，其抑制作用依然存在，但抑制作用明显降低，表明金芪降糖方抑制TG蓄积可能与激活PI3K/AKT和AMPK信号通路有关。结论：“脾主为卫”环节通过促进机体胰岛微循环从而发挥其改善糖脂代谢紊乱的作用，其机制可能与同时干预多条通路以调节疾病状态下失衡的代谢网络相关。
Abstract: Objective: To analyze the molecular biological mechanism of “The Spleen for Defend” regulating glucose and lipid metabolism disorder. Method: The effects of “Jinqi jiangtang” formula on the PI3K/AKT pathway in the liver and muscle of KKAy mice were studied by Western Blot. HepG2 cells were induced by sodium oleate to build lipid accumulation model. Inhibitors such as Com-pound C (AMPK inhibitor), STO-609 (CaMKK inhibitor), Oxtromorine (acetylcholine receptor inhibitors), Cytochalasin B (GLUT4 inhibitors), and agonist IGF-1 (PI3K agonist) were used to explore possible mechanism of lipid regulation. It is suggested that possible mechanism on TG accumulation of “Jinqi jiangtang” formula could inhibit TG accumulation through activating AMPK and PI3K/AKT signaling pathway. Conclusion: The effects of “The Spleen for Defend” on the improvement of the disturbance in the lipid and glucose metabolism may be achieved by promoting islet microcirculation, and its mechanism may be related to intervention of multiple pathways to regulate the unbalanced metabolic network in the state of disease.
文章引用：李莉, 王涛. 探索“脾主为卫”环节对糖脂代谢稳态的调节机制[J]. 中医学, 2021, 10(3): 343-251. https://doi.org/10.12677/TCM.2021.103048

参考文献

[1] Kokubo, Y. (2011) Associations of Impaired Glucose Metabolism and Dyslipidemia with Cardiovascular Diseases: What Have We Learned from Japanese Cohort Studies for Individualized Prevention and Treatment? EPMA Journal, 2, 75-81. [Google Scholar] [CrossRef] [PubMed]
[2] Sasaki, J., Otonari, T., Uchida, Y., et al. (2013) Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study. Journal of Atherosclerosis & Thrombosis, 20, 368-379. [Google Scholar] [CrossRef] [PubMed]
[3] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版) [J]. 中国循环杂志, 2016, 31(10): 937-950.
[4] 郭姣, 肖雪, 荣向路, 等. 糖脂代谢病与精准医学[J]. 世界科学技术–中医药现代化, 2017, 19(1): 50-54.
[5] 王珍, 刘友章, 王秀丽. “脾为之卫”理论浅探[J]. 新中医, 2011, 43(3): 5-7.
[6] 袁卫玲, 苏玮莲, 马佐英, 等. 论中医脾功能变化与糖脂代谢关系[J]. 中国中医药信息杂志, 2015, 22(10): 7-8.
[7] 李晔, 李秋贵. 金芪降糖片治疗2型糖尿病临床经验[J]. 中国中医药现代远程教育, 2005, 3(6): 49-50.
[8] 汪运富. 论“脾主为卫”[J]. 山东中医药大学学报, 2001, 25(3): 209-214.
[9] 李柳梅, 纪云西. 中医“气衰气少”与糖脂物质能量转化[J]. 中华中医药学刊, 2017, 35(11): 2865-2867.
[10] 杨宇峰, 刘军彤. 脾气虚证代谢综合征大鼠血清脂质代谢生物标志物代谢组学研究[J]. 中医药导报, 2020, 26(6): 19-22.
[11] 世界中医药学会联合会代谢病专业委员会. 糖脂代谢病(瘅浊)中西医结合诊疗技术规范[S]. 北京: 中国医药科技出版社, 2019.
[12] 李敏谦, 林育, 项磊, 等. 瘅浊与糖脂代谢病[J]. 世界中医药, 2019, 14(3): 652-655.
[13] 黄建华, 卞琴, 李文伟, 等. 稳态作为中医“证”研究的新思路的依据和意义[J]. 中国中西医结合杂志, 2012, 32(1): 111-114.
[14] 林玉芳, 韩薇, 李寅, 等. 中医药对胰岛素抵抗相关信号通路影响的研究进展[J]. 上海中医药大学学报, 2015, 29(5): 98-101.
[15] 刘桠, 康健, 高泓. 从“脾胰同源”论血糖波动的中医辨治思路[J]. 辽宁中医杂志, 2015, 42(7): 1246-1247.
[16] 刘望舒, 陈筱云. 2型糖尿病胰岛素抵抗与脾的关系探析[J]. 山西中医学院学报, 2016, 17(1): 75-76.